Skip to main content

Table 2 Predictors of early severe anaemia in the first six months of ART initiation

From: Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings

Characteristic

Univariate OR (95% CI)

P-value

Adjusted OR (95% CI)

P-value

Gender

    

   Male

0.71(0.46-1.09)

0.122

  

Age (1 year increase)

0.97(0.87-1.09)

0.662

  

BMI (kg/m2)

0.89(0.84-0.96)

0.001

0.94(0.88-1.01)

0.054

WHO stage

    

I-II

1.00

 

1.00

 

III-IV

1.47(0.93-2.31)

0.095

1.23(0.72-2.09)

0.444

CD4 T cell count

    

200+

1.00

 

1.00

 

50-199

1.05(0.55-2.00)

0.878

0.84(0.41-1.72)

0.631

<50

1.69(0.88-3.23)

0.113

1.11(0.53-2.32)

0.782

HB g/dL,

    

   >8

1.00

 

1.00

 

   ≤8

9.43(5.95-14.93)

<0.0001

5.27(3.00-9.26)

<0.0001

MCV

    

   ≥80

1.00

 

1.00

 

   <80

2.68(1.82-3.93)

<0.0001

1.60 (1.01-2.52)

0.045

TB episode

    

   No

1.00

 

1.00

0.002

   Yes

8.96 (4.46-18.02)

<0.0001

3.69(1.64-8.32)

 

ART Regimen

    

   d4T

1.00

 

1.00

0.209

   AZT

1.17(0.79-1.73)

0.421

1.33 (0.85-2.07)

 
  1. Note : a - p value from overall test for trend in heterogeneity BMI = body mass index, HB = hemoglobin, MCV = mean corpuscular volume, TB = tuberculosis, ART = antiretroviral therapy, d4T = stavudine, AZT = zidovudine, OR = odds ratio